علاج نقائل الجهاز العصبي المركزي في سرطان الرئة غير الصغير الخلايا مع تغيير المحرك الورمي القابل للاستهداف

References

DOI: 10.1016/j.annonc.2021.07.016

• Patients with NSCLC with actionable oncogenic driver alterations such as EGFR or ALK or ROS1 rearrangement and asymptomatic or oligosymptomatic BM should be treated by upfront systemic targeted therapy.
• Adequately designed controlled clinical trials are required to determine whether novel, potent brain-penetrant TKIs, including the third-generation TKI osimertinib, can obviate the need for early SRS.